AMGN250117C335000
- 0.55
- 0.000.00%
Amgen Newsroom
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $350
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370
Jefferies Remains a Buy on Amgen (AMGN)
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Wells Fargo & Co has lowered Amgen's Target Price to 280 dollars.
Gelonghui, January 14 | Wells Fargo & Co: Downgraded Amgen's Target Price from $335 to $280, maintaining a "neutral" rating. (Gelonghui)
Unpacking the Latest Options Trading Trends in Amgen
UnitedHealth, Caterpillar Share Gains Contribute To Dow's 240-Point Climb
Peering Into Amgen's Recent Short Interest
Bernstein Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $280
Express News | Amgen Inc. : Wells Fargo Cuts Target Price to $280 From $335
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Goldman Sachs lowered Amgen's Target Price to $370.
Gelonghui, January 9 | Goldman Sachs: Downgraded Amgen's Target Price from $375 to $370, maintaining a "Buy" rating. (Gelonghui)
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $370
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating
Merck Downgraded by Truist to Hold Over Growth Concerns
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $298